News from a few weeks back is a sound reminder where the SP is heading later this year.
AKE – Credit Suisse rates the stock as Outperform
By Broker News | More Articles by Broker News
MORE ALLKEM LIMITED CONTENT
Credit Suisse has issued another spodumene price increase through to 2023, noting Allkem suggests further upside risk to the broker’s forecasts given high spot pricing.
With a cheaper priced contract set to complete in the June quarter, the broker expects Allkem prices to accelerate towards record spot prices in the December half. Elsewhere, covid impacts have pushed the Sal de Vida startup back six months to the first half of 2023.
The Outperform rating is retained and the target price increases to $13.70 from $13.20.
- Forums
- ASX - By Stock
- Ann: December Quarterly Activities Report
News from a few weeks back is a sound reminder where the SP is...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)